News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Email Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go Advanced Search Keywords Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Feb 5, 2008 Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics Jan 28, 2008 Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis Jan 22, 2008 Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market Dec 18, 2007 Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy Dec 12, 2007 Insmed Awarded $2.1 Million by Muscular Dystrophy Association Dec 6, 2007 Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference Dec 6, 2007 Insmed Appoints Dennis M. Lanfear to Board Of Directors Dec 3, 2007 Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications Nov 13, 2007 Insmed Advances Follow on Biologics Initiative Nov 8, 2007 Insmed Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2007 Show 5102550100 per page«1…46474849505152…69» Stay In The Loop Want to stay up to date on our news, events, and filings? Set up your email alerts. Sign Up View the latest Insmed Investor Presentation Download